What is the optimal management option for occupational asthma?

European Respiratory Review

Volumn 21, Issue 124, 2012, Pages 97-104

  Vandenplas, Olivier ^a   Dressel, Holger ^b   Nowak, Dennis ^c   Jamart, Jacques ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Klinikum Neuperlach   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Asthma; Occupational diseases; Outcome assessment; Prognosis; Respiratory protective devices

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; IMMUNOGLOBULIN E; OMALIZUMAB;

ALLERGY; BRONCHUS HYPERREACTIVITY; DETERIORATION; FORCED EXPIRATORY VOLUME; HUMAN; OCCUPATIONAL ASTHMA; OCCUPATIONAL EXPOSURE; PROGNOSIS; PROTECTIVE EQUIPMENT; REVIEW; RHINOCONJUNCTIVITIS; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW; UNEMPLOYMENT; WORK ENVIRONMENT;

ANTI-ASTHMATIC AGENTS; ASTHMA, OCCUPATIONAL; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HUMANS; OCCUPATIONAL EXPOSURE; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS;

EID: 84860343941     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00004911     Document Type: Review

References (67)

1. Nicholson PJ, Cullinan P, Taylor AJ, et al. Evidence based guidelines for the prevention, identification, and management of occupational asthma. Occup Environ Med 2005; 62: 290-299.
2. Tarlo SM, Balmes J, Balkissoon R, et al. Diagnosis and management of work-related asthma: American College Of Chest Physicians Consensus Statement. Chest 2008; 134: 1S-41S.
3. Fishwick D, Barber CM, Bradshaw LM, et al. Standards of care for occupational asthma. Thorax 2008; 63: 240-250.
4. Vandenplas O, Toren K, Blanc PD. Health and socioeconomic impact of work-related asthma. Eur Respir J 2003; 22: 689-697.
5. Driscoll T, Nelson DI, Steenland K, et al. The global burden of nonmalignant respiratory disease due to occupational airborne exposures. Am J Ind Med 2005; 48: 432-445.
6. Boyd R, Cowie H, Hurley F, et al. The True Cost of Occupational Asthma in Great Britain. Sudbury, Health and Safety Executive, 2006; pp. 1-122.
7. Beach J, Rowe BH, Blitz S, et al. Diagnosis and Management of Work-related Asthma. Evidence Report/Technology Assessment Number 129. AHRQ Publication No 06-E003-2. Rockville, Agency for Healthcare Research and Quality, 2005. www.ahrq.gov/clinic/ epcsums/asthworksum.htm Date last updated: October 2005.
8. Rachiotis G, Savani R, Brant A, et al. Outcome of occupational asthma after cessation of exposure: a systematic review. Thorax 2007; 62: 147-152.
9. Cullinan P. Occupational asthma. Occup Environ Med 2008; 65: 151.
10. Baur X, Sigsgaard T, Aasen T, et al. Overview of the guidelines management of work-related asthma. Eur Respir J 2012; 39: 529-545.
11. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001; 323: 334-336.
12. Wallace BC, Schmid CH, Lau J, et al. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 2009; 9: 80.
13. Chan-Yeung M, MacLean L, Paggiaro PL. Follow-up study of 232 patients with occupational asthma caused by western red cedar (Thuja plicata). J Allergy Clin Immunol 1987; 79: 792-796.
14. Rosenberg N, Garnier R, Rousselin X, et al. Clinical and socioprofessional fate of isocyanate-induced asthma. Clin Allergy 1987; 17: 55-61.
15. Moscato G, Bertoletti R, Biscaldi G, et al. Occupational asthma: fate and management after the diagnosis. G Ital Med Lav 1993; 15: 27-31.
16. Gannon PF, Weir DC, Robertson AS, et al. Health, employment, and financial outcomes in workers with occupational asthma. Br J Ind Med 1993; 50: 491-496.
17. Tarlo SM, Banks D, Liss G, et al. Outcome determinants for isocyanate induced occupational asthma among compensation claimants. Occup Environ Med 1997; 54: 756-761.
18. Orriols R, Drobnic ME, Munoz X, et al. Asma ocupacional por isocianatos: estudio de 21 pacientes [Occupational asthma due to isocyanates: a study of 21 patients]. Med Clin (Barc) 1999; 113: 659-662.
19. Merget R, Schulte A, Gebler A, et al. Outcome of occupational asthma due to platinum salts after transferral to low-exposure areas. Int Arch Occup Environ Health 1999; 72: 33-39.
20. Valentino M, Rapisarda V. Evoluzione dell'asma da isocianati in rapporto alla cessazione dell'esposizione: studio longitudinale su 50 soggetti [Course of isocyanate-induced asthma in relation to exposure cessation: longitudinal study of 50 subjects]. G Ital Med Lav Ergon 2002; 24: 26-31.
21. Padoan M, Pozzato V, Simoni M, et al. Long-term follow-up of toluene diisocyanate-induced asthma. Eur Respir J 2003; 21: 637-640.
22. Lin FJ, Dimich-Ward H, Chan-Yeung M. Longitudinal decline in lung function in patients with occupational asthma due to western red cedar. Occup Environ Med 1996; 53: 753-756.
23. Anees W, Moore VC, Burge PS. FEV1 decline in occupational asthma. Thorax 2006; 61: 751-755.
24. Moscato G, Dellabianca A, Perfetti L, et al. Occupational asthma: a longitudinal study on the clinical and socioeconomic outcome after diagnosis. Chest 1999; 115: 249-256.
25. Marabini A, Siracusa A, Stopponi R, et al. Outcome of occupational asthma in patients with continuous exposure: a 3-year longitudinal study during pharmacologic treatment. Chest 2003; 124: 2372-2376.
26. Sastre J, Quirce S. Immunotherapy: an option in the management of occupational asthma? Curr Opin Allergy Clin Immunol 2006; 6: 96-100.
27. Armentia A, Martin-Santos JM, Quintero A, et al. Bakers' asthma: prevalence and evaluation of immunotherapy with a wheat flour extract. Ann Allergy 1990; 65: 265-272.
28. Armentia A, Arranz M, Martin JM, et al. Evaluation of immune complexes after immunotherapy with wheat flour in bakers' asthma. Ann Allergy 1992; 69: 441-444.
29. Leynadier F, Herman D, Vervloet D, et al. Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers. J Allergy Clin Immunol 2000; 106: 585-590.
30. Sastre J, Fernandez-Nieto M, Rico P, et al. Specific immunotherapy with a standardized latex extract in allergic workers: a doubleblind, placebo-controlled study. J Allergy Clin Immunol 2003; 111: 985-994.
31. Patriarca G, Nucera E, Pollastrini E, et al. Sublingual desensitization: a new approach to latex allergy problem. Anesth Analg 2002; 95: 956-960.
32. Perez Pimiento A, Bueso Fernandez A, Garcia Loria J, et al. Effect of omalizumab treatment in a baker with occupational asthma. J Investig Allergol Clin Immunol 2008; 18: 490-491.
33. Olivieri M, Biscardo CA, Turri S, et al. Omalizumab in persistent severe bakers' asthma. Allergy 2008; 63: 790-791.
34. Brant A, Zekveld C, Welch J, et al. The prognosis of occupational asthma due to detergent enzymes: clinical, immunological and employment outcomes. Clin Exp Allergy 2006; 36: 483-488.
35. Klusackova P, Pelclova D, Jindriska Levedova D, et al. Occupational asthma after withdrawal from the occupational allergen exposure. Ind Health 2006; 44: 629-638.
36. Labrecque M, Khemici E, Cartier A, et al. Impairment in workers with isocyanate-induced occupational asthma and removed from exposure in the province of Quebec between 1985 and 2002. J Occup Environ Med 2006; 48: 1093-1098.
37. Park HW, Kim DI, Sohn SW, et al. Outcomes in occupational asthma caused by reactive dye after long-term avoidance. Clin Exp Allergy 2007; 37: 225-230.
38. Park JW, Yang JY, Kim CW, et al. Avoidance therapy in reactive dye-induced occupational asthma: long-term follow-up. Ann Allergy Asthma Immunol 2006; 97: 551-556.
39. Pisati G, Baruffini A, Bernabeo F, et al. Rechallenging subjects with occupational asthma due to toluene diisocyanate (TDI), after longterm removal from exposure. Int Arch Occup Environ Health 2007; 80: 298-305.
40. Yacoub MR, Lavoie K, Lacoste G, et al. Assessment of impairment/ disability due to occupational asthma through a multidimensional approach. Eur Respir J 2007; 29: 889-896.
41. Munoz X, Gomez-Olles S, Cruz MJ, et al. Evolucion de la hiperrespuesta bronquial en pacientes con asma ocupacional por exposicion a sales de persulfato [Course of bronchial hyperresponsiveness in patients with occupational asthma caused by exposure to persulfate salts]. Arch Bronconeumol 2008; 44: 140-145.
42. Malo JL, Ghezzo H. Recovery of methacholine responsiveness after end of exposure in occupational asthma. Am J Respir Crit Care Med 2004; 169: 1304-1307.
43. Maghni K, Lemière C, Ghezzo H, et al. Airway inflammation after cessation of exposure to agents causing occupational asthma. Am J Respir Crit Care Med 2004; 169: 367-372.
44. Piirila PL, Meuronen A, Majuri ML, et al. Inflammation and functional outcome in diisocyanate-induced asthma after cessation of exposure. Allergy 2008; 63: 583-591.
45. Sumi Y, Foley S, Daigle S, et al. Structural changes and airway remodelling in occupational asthma at a mean interval of 14 years after cessation of exposure. Clin Exp Allergy 2007; 37: 1781-1787.
46. Maestrelli P, De Marzo N, Saetta M, et al. Effects of inhaled beclomethasone on airway responsiveness in occupational asthma. Placebo-controlled study of subjects sensitized to toluene diisocyanate. Am Rev Respir Dis 1993; 148: 407-412.
47. Malo JL, Cartier A, Côté J, et al. Influence of inhaled steroids on recovery from occupational asthma after cessation of exposure: an 18-month double-blind crossover study. Am J Respir Crit Care Med 1996; 153: 953-960.
48. Burge PS. Occupational asthma in electronics workers caused by colophony fumes: follow-up of affected workers. Thorax 1982; 37: 348-353.
49. Paggiaro PL, Vagaggini B, Dente FL, et al. Bronchial hyperresponsiveness and toluene diisocyanate. Long-term change in sensitized asthmatic subjects. Chest 1993; 103: 1123-1128.
50. Pisati G, Baruffini A, Zedda S. Toluene diisocyanate induced asthma: outcome according to persistence or cessation of exposure. Br J Ind Med 1993; 50: 60-64.
51. Vandenplas O, Jamart J, Delwiche JP, et al. Occupational asthma caused by natural rubber latex: outcome according to cessation or reduction of exposure. J Allergy Clin Immunol 2002; 109: 125-130.
52. Bernstein DI, Karnani R, Biagini RE, et al. Clinical and occupational outcomes in health care workers with natural rubber latex allergy. Ann Allergy Asthma Immunol 2003; 90: 209-213.
53. Vandenplas O, Dressel H, Wilken D, et al. Management of occupational asthma: cessation or reduction of exposure? Eur Respir J 2011; 38: 804-811.
54. Muller-Wening D, Neuhauss M. Protective effect of respiratory devices in farmers with occupational asthma. Eur Respir J 1998; 12: 569-572.
55. Laoprasert N, Swanson MC, Jones RT, et al. Inhalation challenge testing of latex-sensitive health care workers and the effectiveness of laminar flow HEPA-filtered helmets in reducing rhinoconjunctival and asthmatic reactions. J Allergy Clin Immunol 1998; 102: 998-1004.
56. Slovak AJ, Orr RG, Teasdale EL. Efficacy of the helmet respirator in occupational asthma due to laboratory animal allergy (LAA). Am Ind Hyg Assoc J 1985; 46: 411-415.
57. Kongerud J, Rambjor O. The influence of the helmet respirator on peak flow rate in aluminum potroom. Am Ind Hyg Assoc J 1991; 52: 243-248.
58. Taivainen AI, Tukiainen HO, Terho EO, et al. Powered dust respirator helmets in the prevention of occupational asthma among farmers. Scand J Work Environ Health 1998; 24: 503-507.
59. Côté J, Kennedy S, Chan-Yeung M. Outcome of patients with cedar asthma with continuous exposure. Am Rev Respir Dis 1990; 141: 373-376.
60. Royal College of General Practitioners. The Development and Implementation of Clinical Guidelines: Report of the Clinical Guidelines Working Group. London, Royal College of General Practitioners, 1995.
61. Banks DE, Rando RJ, Barkman HW Jr. Persistence of toluene diisocyanate-induced asthma despite negligible workplace exposures. Chest 1990; 97: 121-125.
62. O'Donnell TV, Welford B, Coleman ED. Potroom asthma: New Zealand experience and follow-up. Am J Ind Med 1989; 15: 43-49.
63. Harries MG, Burge PS, Samson M, et al. Isocyanate asthma: respiratory symptoms due to 1,5-naphthylene di-isocyanate. Thorax 1979; 34: 762-766.
64. Grammer LC, Shaughnessy MA, Kenamore BD. Clinical and immunologic outcome of 42 individuals with trimellitic anhydride-induced immunologic lung disease after transfer to low exposure. Allergy Asthma Proc 2000; 21: 355-359.
65. Smith TA, Patton J. Health surveillance in milling, baking and other food manufacturing operations-five years' experience. Occup Med (Lond) 1999; 49: 147-153.
66. Munoz X, Cruz MJ, Orriols R, et al. Occupational asthma due to persulfate salts: diagnosis and follow-up. Chest 2003; 123: 2124-2129.
67. Schunemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006; 174: 605-614.